PERIPHERAL T-CELL LYMPHOMA

This study tests whether the drug golidocitinib can help keep peripheral T-cell lymphoma from coming back after initial chemotherapy. It is for patients who had a good response to their first treatment but cannot have a stem cell transplant. Participants take either golidocitinib…

This early-phase trial tests a new drug called ST-001 (a form of fenretinide) in people with T-cell non-Hodgkin lymphoma whose cancer has returned or not responded to prior treatments. The main goal is to find the safest dose and understand side effects. About 46 participants wil…

This study tests a new type of CAR-T cell therapy that targets two different markers on cancer cells at once. It is for adults with blood cancers like leukemia, lymphoma, or myeloma that have come back or not responded to other treatments. The goal is to see if this dual-target a…

This study tests an experimental drug called HH2853 in people with certain blood cancers (non-Hodgkin's lymphomas) or advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 254 adults will…

This study tests a new combination of two targeted drugs (linperlisib and chidamide) against standard chemotherapy (CHOP) for people with a rare blood cancer called peripheral T-cell lymphoma. The goal is to see if the new combo works better at controlling the disease. The study …

This program offers the investigational drug selinexor to people with multiple myeloma, lymphoma, sarcoma, or other cancers who have run out of approved treatments and cannot join a clinical trial. It is not a cure but aims to control the disease. Patients must get approval from …

This phase 3 study tests whether adding either Beleodaq or Folotyn to standard chemotherapy (CHOP) helps people with newly diagnosed peripheral T-cell lymphoma live longer without their cancer getting worse. About 504 participants will be randomly assigned to one of three treatme…

This study tests whether the drug ruxolitinib can help prevent T-cell lymphoma from returning and reduce graft-versus-host disease (GVHD) after a stem cell transplant. About 44 adults with T-cell lymphoma who are in remission after transplant will take ruxolitinib as a maintenanc…

This study is for people with peripheral T-cell lymphoma whose cancer did not shrink or got worse after standard first chemotherapy. It compares two approaches: a donor stem cell transplant (allogeneic HSCT) or other rescue treatments. The goal is to see which option helps patien…

This early-phase trial tests a specially modified virus (VSV-hIFNβ-NIS) combined with two immunotherapy drugs (ipilimumab and cemiplimab) in adults with relapsed or refractory T-cell lymphoma. The virus is designed to kill cancer cells without harming healthy ones, while the immu…

This study tests a combination of two drugs, sintilimab and chidamide, in 51 adults with a rare type of lymphoma (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. The goal is to see if this combination can control the disease and how safe it is. Pa…

This study tests a new drug called golidocitinib against standard treatments for adults with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or not responded to prior therapy. About 218 participants will be randomly assigned to receive either golidociti…

This study tests whether the drug golidocitinib, given alone or with standard chemotherapy (CHOP), can help control peripheral T cell lymphoma (PTCL) in people who are newly diagnosed. About 30 adults will take part at MD Anderson Cancer Center. The main goal is to check safety a…

This early-stage study tests a new approach for people with certain lymphomas (like Hodgkin lymphoma) that have come back or not responded to standard treatments. Researchers take immune cells from healthy donors, add a special receptor (C7R) to help them survive longer, and targ…

This study tests a new drug called CCS1477 in people with advanced blood cancers like leukemia, lymphoma, and multiple myeloma that have not responded to standard treatments. The main goals are to check the drug's safety and find the right dose. About 250 participants will receiv…

This study tests a new treatment for people with a rare blood cancer called peripheral T-cell lymphoma that has not responded to standard therapy or has returned. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells c…

This study is for people with peripheral T-cell lymphoma, a rare blood cancer, that has returned or not improved after standard treatment. Researchers are testing a new drug called golidocitinib combined with either mitoxantrone liposome or chidamide to see if the combination is …

This study tests whether adding the experimental drug lacutamab to standard chemotherapy helps people with a rare type of blood cancer (peripheral T-cell lymphoma) that has returned or stopped responding to treatment. About 56 adults whose cancer cells have a specific marker call…

This study tests whether adding ruxolitinib to the immunotherapy drug pembrolizumab is safe and effective for people with certain lymphomas that have come back or not responded to treatment. About 53 adults with Hodgkin or non-Hodgkin lymphoma will receive the combination. The go…

This early-phase trial tests whether a patient's own immune cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory p…

This study looks at people with peripheral T-cell lymphoma whose cancer went away after their first treatment. It compares two options: getting a stem cell transplant using their own cells or simply being watched closely. The goal is to see which approach helps keep the cancer fr…

This study tests whether a combination of two drugs, cidabenamine and azacitidine, can keep high-risk peripheral T-cell lymphoma from coming back after a stem cell transplant. About 40 adults aged 18 to 70 will receive this maintenance therapy. The goal is to improve survival and…

This study looks at two types of stem cell transplants for people with a rare blood cancer called peripheral T-cell lymphoma that only partially improved after initial treatment. One group receives their own stem cells, while the other gets stem cells from a healthy donor. The go…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study will follow about 3,000 people in China with peripheral T-cell lymphoma, a rare blood cancer. Researchers will look at how the disease is treated in everyday practice, what genetic changes occur, and how long patients live. The goal is to learn more about the disease a…